Amid the ongoing Covid-19 pandemic and the crisis created by it, JB Chemicals & Pharmaceuticals has emerged as the fastest growing pharmaceuticals company amongst the top 25 companies in the Indian Pharmaceutical Market during the Financial Year 2021-22 registering an impressive growth rate of 29% outperforming the market rate of 18% as per the moving annual turnover (MAT) basis in March 2022. More so, 5 brands of JBCPL are ranked in the top 300 pharmaceutical brands of the Indian Pharmaceutical Market, the company shared in a release.

Elated on the spectacular growth of JBCPL, Nikhil Chopra, CEO & Whole Time Director, JBCPL said, “We have made a remarkable growth during the financial year 2021-22. Though currently, we are ranked 25 in the Indian Pharmaceutical Market, we target to have the company rank in the top 20 pharmaceutical firms. We have outperformed in the cardiac segment with 3 of its brands marking their presence in the top 300 brands of Indian Pharmaceutical Market.”

The company has also moved up from rank 32 as of moving annual turnover (MAT) March 2020 to rank 25 in March 2022 and with the newly acquired brands from Sanzyme and the latest addition of Azmarda from April 2022, JBCPL is likely to move even further up, the release further stated.

JB sales as per IQVIA MAT 22 was at Rs 1490.7 crore as compared to Rs 1157.4 crore a year earlier recording a growth of 28.8 % for FY 22. JB was the fastest growing pharmaceutical company in FY 2021-22. The second fastest-growing pharma company among the top 25 as per IQVIA is Alkem which recorded sales as per IQVIA MAT 22 at Rs 7244 crore as compared to Rs 5676 crore growing at 27.6 % for the financial year. The third fastest-growing pharma company among the top 25 as per IQVIA is ARISTO which recorded sales as per IQVIA MAT 22 at Rs 5459 crore as compared to Rs 4352 crore growing at 25.4 % for the financial year.

“We are delighted to be the fastest-growing company in the FY 2021-22. This has been possible because of the continued focus on its core therapy areas. Further, this growth has been achieved with an insignificant contribution from the Covid-19 portfolio, which reflects the underlying growth momentum of our core business. We remain confident that we will continue to outperform the Indian Pharmaceutical Market (IPM), and drive growth by focusing on our core therapy areas. Last year, we focused on building capabilities and focused on building a culture that will drive growth. We reached out to every employee to build a cohesive culture,” said, Dilip Singh Rathore, President, Domestic Business, JBCPL.

With the strong placement in the cardiac segment, JBCPL has moved up three ranks in the therapy from 16 as moving annual turnover (MAT) from March 2020 to 13 by March 2022, while growing with a CAGR of 22.73%, beating the segment growth rate which is 12% over the same period. 4 of JB’s brands (including Azmarda) rank in Top 100 in the Therapy, all growing at a very healthy pace.